• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲磺酸伊马替尼抑制白细胞介素-7诱导的信号转导和转录激活因子5(STAT5)磷酸化,并导致慢性粒细胞白血病患者出现T细胞淋巴细胞减少。

Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients.

作者信息

Thiant S, Moutuou M M, Laflamme P, Sidi Boumedine R, Leboeuf D M, Busque L, Roy J, Guimond M

机构信息

Division d'Hématologie-Oncologie, Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada.

Départment de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, Québec, Canada.

出版信息

Blood Cancer J. 2017 Apr 7;7(4):e551. doi: 10.1038/bcj.2017.29.

DOI:10.1038/bcj.2017.29
PMID:28387753
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5436073/
Abstract

Imatinib mesylate (IM) therapy has been shown to induce lower T cell counts in chronic myelogenous leukemia (CML) patients and an interference of IM with T cell receptor (TCR) signaling has been invoked to explain this observation. However, IL-7 and TCR signaling are both essential for lymphocyte survival. This study was undertaken to determine whether IM interferes with IL-7 or TCR signaling to explain lower T cell counts in patients. At diagnosis, CML patients have typically lower CD4 counts in their blood, yet CD8 counts are normal or even increased in some. Following the initiation of IM treatment, CD4 counts were further diminished and CD8 T lymphocytes were dramatically decreased. In vitro studies confirmed IM interference with TCR signaling through the inhibition of ERK phosphorylation and we showed a similar effect on IL-7 signaling and STAT5 phosphorylation (STAT5-p). Importantly however, using an in vivo mouse model, we demonstrated that IM impaired T cell survival through the inhibition of IL-7 and STAT5-p but not TCR signaling which remained unaffected during IM therapy. Thus, off-target inhibitory effects of IM on IL-7 and STAT5-p explain how T cell lymphopenia occurs in patients treated with IM.

摘要

甲磺酸伊马替尼(IM)治疗已被证明会导致慢性粒细胞白血病(CML)患者的T细胞计数降低,有人提出IM对T细胞受体(TCR)信号传导的干扰来解释这一观察结果。然而,白细胞介素-7(IL-7)和TCR信号传导对淋巴细胞存活均至关重要。本研究旨在确定IM是否干扰IL-7或TCR信号传导,以解释患者T细胞计数降低的原因。在诊断时,CML患者血液中的CD4计数通常较低,但在某些患者中CD8计数正常甚至升高。开始IM治疗后,CD4计数进一步减少,CD8 T淋巴细胞显著减少。体外研究证实IM通过抑制细胞外信号调节激酶(ERK)磷酸化干扰TCR信号传导,并且我们对IL-7信号传导和信号转导及转录激活因子5磷酸化(STAT5-p)也显示出类似作用。然而,重要的是,使用体内小鼠模型,我们证明IM通过抑制IL-7和STAT5-p损害T细胞存活,但不影响TCR信号传导,在IM治疗期间TCR信号传导保持未受影响。因此,IM对IL-7和STAT5-p的脱靶抑制作用解释了接受IM治疗的患者中T细胞淋巴细胞减少的发生机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c04d/5436073/8aec222412f3/bcj201729f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c04d/5436073/50a5328d23a1/bcj201729f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c04d/5436073/8aec222412f3/bcj201729f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c04d/5436073/50a5328d23a1/bcj201729f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c04d/5436073/8aec222412f3/bcj201729f2.jpg

相似文献

1
Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients.甲磺酸伊马替尼抑制白细胞介素-7诱导的信号转导和转录激活因子5(STAT5)磷酸化,并导致慢性粒细胞白血病患者出现T细胞淋巴细胞减少。
Blood Cancer J. 2017 Apr 7;7(4):e551. doi: 10.1038/bcj.2017.29.
2
BM microenvironmental protection of CML cells from imatinib through Stat5/NF-κB signaling and reversal by Wogonin.骨髓微环境通过Stat5/NF-κB信号通路对慢性粒细胞白血病细胞起到伊马替尼保护作用,而汉黄芩素可逆转此作用。
Oncotarget. 2016 Apr 26;7(17):24436-54. doi: 10.18632/oncotarget.8332.
3
Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib.持续的 STAT5 介导的 ROS 产生和异常 p53 凋亡信号转导在慢性髓细胞白血病对伊马替尼耐药中的作用。
Int J Mol Med. 2018 Jan;41(1):455-463. doi: 10.3892/ijmm.2017.3205. Epub 2017 Oct 20.
4
Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway.新型长链非编码 RNA-IUR 通过调控 STAT5-CD71 通路抑制 Bcr-Abl 诱导的肿瘤发生。
Mol Cancer. 2019 Apr 8;18(1):84. doi: 10.1186/s12943-019-1013-3.
5
Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors.甲磺酸伊马替尼抑制CD4+ CD25+调节性T细胞活性,并增强针对BCR-ABL肿瘤的主动免疫治疗。
J Immunol. 2008 Nov 15;181(10):6955-63. doi: 10.4049/jimmunol.181.10.6955.
6
A novel mechanism for imatinib mesylate (STI571) resistance in CML cell line KT-1: role of TC-PTP in modulating signals downstream from the BCR-ABL fusion protein.慢性粒细胞白血病细胞系KT-1中对甲磺酸伊马替尼(STI571)耐药的一种新机制:酪氨酸磷酸酶非受体型(TC-PTP)在调节BCR-ABL融合蛋白下游信号中的作用
Exp Hematol. 2004 Nov;32(11):1057-63. doi: 10.1016/j.exphem.2004.07.024.
7
Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells.白藜芦醇通过抑制 Bcr-Abl 和 PKC 信号转导增强慢性髓性白血病细胞对伊马替尼的敏感性。
Chem Biol Interact. 2015 Dec 5;242:195-201. doi: 10.1016/j.cbi.2015.10.004. Epub 2015 Oct 9.
8
Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.达沙替尼(BMS-354825)抑制慢性粒细胞白血病细胞中与凋亡相关的Stat5信号传导。
Mol Cancer Ther. 2007 Apr;6(4):1400-5. doi: 10.1158/1535-7163.MCT-06-0446.
9
Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia.甲磺酸伊马替尼可抑制慢性粒细胞白血病患者活化的CD4 T细胞的细胞因子合成。
Leukemia. 2005 Nov;19(11):1905-11. doi: 10.1038/sj.leu.2403933.
10
CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia.CM363,一种新型萘醌衍生物,它作为多激酶调节剂,可克服慢性粒细胞白血病中的伊马替尼耐药性。
Oncotarget. 2017 May 2;8(18):29679-29698. doi: 10.18632/oncotarget.11425.

引用本文的文献

1
Phase II trial of imatinib mesylate in patients with PDGFRA/B-negative hypereosinophilic syndrome.甲磺酸伊马替尼治疗血小板衍生生长因子受体A/B阴性高嗜酸性粒细胞综合征患者的II期试验。
Br J Haematol. 2024 Dec;205(6):2305-2314. doi: 10.1111/bjh.19828. Epub 2024 Oct 10.
2
Unveiling IL6R and MYC as Targeting Biomarkers in Imatinib-Resistant Chronic Myeloid Leukemia through Advanced Non-Invasive Apoptosis Detection Sensor Version 2 Detection.揭示通过先进的非侵入性凋亡检测传感器版本 2 检测,IL6R 和 MYC 作为伊马替尼耐药慢性髓性白血病的靶向生物标志物。
Cells. 2024 Apr 2;13(7):616. doi: 10.3390/cells13070616.
3
Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia.

本文引用的文献

1
Homeostatic cytokines in immune reconstitution and graft-versus-host disease.免疫重建和移植物抗宿主病中的稳态细胞因子
Cytokine. 2016 Jun;82:24-32. doi: 10.1016/j.cyto.2016.01.003. Epub 2016 Feb 1.
2
Stromal-Derived Factor-1α and Interleukin-7 Treatment Improves Homeostatic Proliferation of Naïve CD4(+) T Cells after Allogeneic Stem Cell Transplantation.基质衍生因子-1α和白细胞介素-7治疗可改善异基因干细胞移植后初始CD4(+) T细胞的稳态增殖。
Biol Blood Marrow Transplant. 2015 Oct;21(10):1721-31. doi: 10.1016/j.bbmt.2015.06.019. Epub 2015 Jul 4.
3
Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia.
伊马替尼治疗慢性髓性白血病后免疫性血小板减少症的改善。
Int J Hematol. 2023 Apr;117(4):613-617. doi: 10.1007/s12185-022-03492-9. Epub 2022 Nov 14.
4
Restoring T Cell Homeostasis After Allogeneic Stem Cell Transplantation; Principal Limitations and Future Challenges.异基因造血干细胞移植后 T 细胞稳态的恢复:主要限制因素和未来挑战。
Front Immunol. 2018 Jun 18;9:1237. doi: 10.3389/fimmu.2018.01237. eCollection 2018.
Ph 阳性急性淋巴细胞白血病成人患者中采用减低强度化疗联合伊马替尼的随机研究。
Blood. 2015 Jun 11;125(24):3711-9. doi: 10.1182/blood-2015-02-627935. Epub 2015 Apr 15.
4
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD.39 例接受伊马替尼治疗的激素难治性慢性移植物抗宿主病患者的 NIH 反应标准的长期结果和前瞻性验证。
Blood. 2013 Dec 12;122(25):4111-8. doi: 10.1182/blood-2013-05-494278. Epub 2013 Oct 23.
5
TCR triggering modulates the responsiveness and homeostatic proliferation of CD4+ thymic emigrants to IL-7 therapy.T 细胞受体的触发调节了 CD4+胸腺迁出细胞对 IL-7 治疗的反应性和稳态增殖。
Blood. 2013 Jun 6;121(23):4684-93. doi: 10.1182/blood-2012-09-458174. Epub 2013 Apr 23.
6
Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD.甲磺酸伊马替尼在激素难治性硬皮病样慢性移植物抗宿主病中的疗效和耐受性有限。
Blood. 2012 Dec 13;120(25):5089-90. doi: 10.1182/blood-2012-09-453928.
7
Imatinib sensitizes T-cell lymphocytes from chronic myeloid leukemia patients to FasL-induced cell death: a brief communication.伊马替尼使慢性髓性白血病患者的 T 细胞淋巴细胞对 FasL 诱导的细胞死亡敏感:一项简要沟通。
J Immunother. 2012 Feb-Mar;35(2):154-8. doi: 10.1097/CJI.0b013e318243f238.
8
Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse.在清髓性 BMT 后第一个月的血浆中,IL-7 和 IL-15 的水平是急性移植物抗宿主病和复发的预测性生物标志物。
Bone Marrow Transplant. 2010 Oct;45(10):1546-52. doi: 10.1038/bmt.2010.13. Epub 2010 Mar 1.
9
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.伊马替尼在慢性期慢性髓性白血病中的药代动力学及其与疗效和安全性的相关性:IRIS研究的亚组分析
Blood. 2008 Apr 15;111(8):4022-8. doi: 10.1182/blood-2007-10-116475. Epub 2008 Feb 6.
10
Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia.细胞因子依赖性伊马替尼耐药在小鼠BCR-ABL+、Arf基因缺失的淋巴细胞白血病中的情况
Genes Dev. 2007 Sep 15;21(18):2283-7. doi: 10.1101/gad.1588607. Epub 2007 Aug 30.